Zulfa Omer
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Zulfa Omer sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Zulfa Omer: 3 sponsored US clinical trials, 3 recruiting.
Zulfa Omer sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Small Lymphocytic Lymphoma, with 3 trials.
Upper-quartile sponsor footprint
Zulfa Omer sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
NCT07014917
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
NCT07108998
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
NCT06978088
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
What is open in the Zulfa Omer pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Small Lymphocytic Lymphoma (3 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Zulfa Omer: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Zulfa Omer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Zulfa Omer page
3 registered trials is a research-attention snapshot, not an endorsement of Zulfa Omer or any single study.
- 3 of Zulfa Omer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Small Lymphocytic Lymphoma is the condition Zulfa Omer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Small Lymphocytic Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Zulfa Omer pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.